HER-2 positive gastric cancer: Current targeted treatments

被引：2

作者：

Malla, Rama Rao ^{[1
]}

Nellipudi, Haasita Reddy ^{[2
]}

Srilatha, Mundla ^{[3
]}

Nagaraju, Ganji Purnachandra ^{[4
]}

机构：

[1] Gandhi Inst Technol & Management Deemed Be Univ, Canc Biol Lab, Inst Sci, Dept Biochem & Bioinformat, Visakhapatnam 530045, AP, India

[2] McMaster Univ, Sch Sci, Hamilton, ON L8S 4L8, Canada

[3] Sri Venkateswara Univ, Dept Biotechnol, Tirupati 517502, AP, India

[4] Univ Alabama Birmingham, Sch Med, Div Hematol & Oncol, Birmingham, AL 35294 USA

来源：

INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES | 2024年 / 274卷

关键词：

Gastric cancer; Metastasis; Resistance; Signaling; Adjunct therapies; TRASTUZUMAB EMTANSINE; OPEN-LABEL; GASTROESOPHAGEAL JUNCTION; PROTEIN EXPRESSION; SINGLE-ARM; ADENOCARCINOMA; ESOPHAGEAL; RESISTANCE; LAPATINIB; 1ST-LINE;

D O I：

10.1016/j.ijbiomac.2024.133247

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Gastric cancer (GC) is highly metastatic and characterized by HER2 amplification. Aberrant HER2 expression drives metastasis, therapy resistance, and tumor recurrence. HER2 amplification contributes to drug resistance by upregulating DNA repair enzymes and drug afflux proteins, reducing drug efficacy. HER2 modulates transcription factors critical for cancer stem cell properties, further impacting drug resistance. HER2 activity is influenced by HER-family ligands, promoting oncogenic signaling. These features point to HER2 as a targetable driver in GC. This review outlines recent advances in HER2-mediated mechanisms and their upstream and downstream signaling pathways in GC. Additionally, it discusses preclinical research investigation that comprehends trastuzumab-sensitizing phytochemicals, chemotherapeutics, and nanoparticles as adjunct therapies. These developments hold promise for improving outcomes and enhancing the management of HER2-positive GC.

引用

页数：9

共 50 条

[1] Recent Advances in Systemic Treatments for HER-2 Positive Advanced Gastric Cancer
Kahraman, Seda
Yalcin, Suayib
ONCOTARGETS AND THERAPY, 2021, 14 : 4149 - 4162
[2] Immune checkpoint inhibitors combined with HER-2 targeted therapy in HER-2 positive gastroesophageal cancer
Aisa, Adilai
Weng, Shanshan
Li, Xinyu
Zhang, Ding
Yuan, Ying
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2022, 180
[3] Challenges and future of HER2-positive gastric cancer therapy
Ma, Chenzhe
Wang, Xiao
Guo, Jiwu
Yang, Bo
Li, Yumin
FRONTIERS IN ONCOLOGY, 2023, 13
[4] Recent Progress in Treatment for HER2-Positive Advanced Gastric Cancer
Kawakami, Takeshi
Yamazaki, Kentaro
CANCERS, 2024, 16 (09)
[5] Impact of Her-2-Targeted Therapy on Overall Survival in Patients With Her-2 Positive Metastatic Breast Cancer
Berghoff, Anna S.
Bago-Horvath, Zsuzsanna
Dubsky, Peter
Rudas, Margaretha
Pluschnig, Ursula
Wiltschke, Christoph
Gnant, Michael
Steger, Guenther G.
Zielinski, Christoph C.
Bartsch, Rupert
BREAST JOURNAL, 2013, 19 (02) : 149 - 155
[6] Emerging Targeted Therapies for HER2 Positive Gastric Cancer That Can Overcome Trastuzumab Resistance
Mitani, Seiichiro
Kawakami, Hisato
CANCERS, 2020, 12 (02)
[7] Advanced HER2-positive gastric cancer: Current and future targeted therapies
Pazo Cid, Roberto A.
Anton, Antonio
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2013, 85 (03) : 350 - 362
[8] Targeted therapies of HER2-positive gastric adenocarcinoma
Schulze, Arik Bernard
Kerkhoff, Andrea
Lenz, Georg
Kessler, Torsten
TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S177 - S180
[9] Immunotherapy for HER-2 positive breast cancer
Yang, Tingting
Kang, Lihua
Li, Dan
Song, Yanqiu
FRONTIERS IN ONCOLOGY, 2023, 13
[10] Adding of apatinib and camrelizumab to overcome de novo trastuzumab resistance of HER2-positive gastric cancer: A case report and literature review
Lv, Huifang
He, Yunduan
Nie, Caiyun
Du, Feng
Chen, Xiaobing
FRONTIERS IN PHARMACOLOGY, 2023, 13

← 1 2 3 4 5 →